Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension

References

• Lv Y, Zhang Y, Shi W, Liu J, Li Y, Zhou Z, He Q, Wei S, Liu J, Quan J. The association between endocan levels and subclinical atherosclerosis in patients with type 2 diabetes mellitus. Am J Med Sci. 2017;353(5):433–38. doi:10.1016/j.amjms.2017.02.004.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43. doi:10.1161/hc0902.104353.
   PubMed Web of Science ®Google Scholar
• Thompson JC, Patricia GW, Wyllie AP, Wyllie AK, Tannock LR. Elevated circulating TGF-B is not the cause of increased arherosclerosis development in biglycan deficient mice. Atherosclerosis. 2018;268:68–75. doi:10.1016/j.atherosclerosis.2017.11.005.
   PubMed Web of Science ®Google Scholar
• Mandraffino G, Aragona CO, Scuruchi M, Mamone F, D’Ascola A, Alibrandi A, Cinquegrani M, Morace C, Oreto L, Saitta C, et al. Biglycan expression, earlier vascular damage and pro-atherogenic profile improvement after smoke cessation in young people. Atherosclerosis. 2017;257:109–15.
   PubMed Web of Science ®Google Scholar
• Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R, Tonnel AB. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):2058–64. doi:10.1074/jbc.271.34.20458.
   Web of Science ®Google Scholar
• Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta Bioenerg. 2006;1765(1):25–37. doi:10.1016/j.bbcan.2005.08.004.
   PubMed Web of Science ®Google Scholar
• Afsar B, Takir M, Kostek O, Covic A, Kanbay M. Endocan: a new molecule playing a role in the development of hypertension and chronic kidney disease? J Clin Hypertens (Greenwich). 2014;16(12):914–16. doi:10.1111/jch.12440.
   PubMed Web of Science ®Google Scholar
• Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis. 2015;243:339–43. doi:10.1016/j.atherosclerosis.2015.09.030.
   PubMed Web of Science ®Google Scholar
• Kanbay M, Afsar B, Gusbeth-Tatomir P, Covic A. Arterial stiffness in dialysis patients: where are we now? Int Urol Nephrol. 2010;42:741–52. doi:10.1007/s11255-009-9675-1.
   PubMed Web of Science ®Google Scholar
• Shirwany NA, Zou M. Arterial stiffness: A brief review. Acta Pharmacol Sin. 2010;31:1267–76. doi:10.1038/aps.2010.123.
   PubMed Web of Science ®Google Scholar
• Jatoi NA, Mahmud A, Bennett K, Feely J. Assessment of arterial stiffness in hypertension: Comparisson of ocillometric (Arteriograph), piezoelectronic (Complior) and tonometric (SphygmoCor) techniques. J Hypertens. 2009;27:2186–91. doi:10.1097/HJH.0b013e32833057e8.
   PubMed Web of Science ®Google Scholar
• Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M, Celik T, Turker T, Iyisoy A. Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773–77. doi:10.1177/0003319713513492.
   PubMed Web of Science ®Google Scholar
• Çimen T, Bilgin M, Akyel A, Felekoğlu MA, Nallbani A, Özdemir Ş, Erden G, Öztürk A, Doğan M, Yeter E. Endocan and non-dipping circadian pattern in newly diagnosed essential hypertension. Korean Circ J. 2016;46(6):827–33. doi:10.4070/kcj.2016.46.6.827.
   PubMed Web of Science ®Google Scholar
• Tadzic R, Mihalj M, Vcev A, Ennen J, Tadzic A, Drenjancevic I. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Pressure Res. 2013;37(2–3):103–15. doi:10.1159/000350064.
   PubMed Web of Science ®Google Scholar
• Celık T, Balta S, Karaman M, Ahmet AS, Demırkol S, Ozturk C, Dınc M, Unal HU, Yılmaz MI, Kılıc S, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015;24(1):55–60. doi:10.3109/08037051.2014.972816.
   PubMed Web of Science ®Google Scholar
• Balta I, Balta S, Demirkol S, Mikhailidis D, Celik T, Akhan M, Kurt O, Kurt YG. Aydin I and Kilic S. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. BrJ Dermatol. 2013;169(5):1066–70. doi:10.1111/bjd.12525.
   PubMed Web of Science ®Google Scholar
• Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T, Cakar M, Kucuk U. Eksioglu M and Kurt YG. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70(2):291–96. doi:10.1016/j.jaad.2013.09.013.
   PubMed Web of Science ®Google Scholar
• Icli A, Cure E, Cure MC, Uslu AU, Balta S, Mikhailidis DP, Ozturk C, Arslan S, Sakız D, Sahin M, et al. Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology. 2016;67(8):749–55. doi:10.1177/0003319715616240.
   PubMed Web of Science ®Google Scholar
• Segura J, Campo C, Ruilope LM. Proteinuria: an underappreciated risk factor in cardiovascular disease. Curr Cardiol Rep. 2002;4(6):458–62.
   PubMedGoogle Scholar
• Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese VM. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens. 1994;7(1):23–29. doi:10.1093/ajh/7.1.23.
   PubMed Web of Science ®Google Scholar
• Pedrinelli R, Dell’Omo G, Penno G, Bandinelli S, Bertini A, Di Bello V, Mariani M. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension. 2000;35(1):48–54. doi:10.1161/01.hyp.35.1.48.
   PubMed Web of Science ®Google Scholar
• Pontremoli R, Nicolella C, Viazzi F, Ravera M, Sofia A, Berruti V, Bezante GP, Del Sette M, Martinoli C, Sacchi G, et al. Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens. 1998;11(4):430–38. doi:10.1016/s0895-7061(97)00498-6.
   PubMed Web of Science ®Google Scholar
• Arman Y, Akpinar TS, Kose M, Emet S, Yuruyen G, Akarsu M, Ozcan M, Yegit O, Cakmak R, Altun O, et al. Effect of glycemic regulation on endocan levels in patients with diabetes: a preliminary study. Angiology. 2016;67(3):239–44. doi:10.1177/0003319715585664.
   PubMed Web of Science ®Google Scholar
• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–09. doi:10.1038/362801a0.
   PubMed Web of Science ®Google Scholar
• Davies JI, Struthers AD. Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weaknesses. J Hypertens. 2003;21(3):463–72. doi:10.1097/01.hjh.0000052468.40108.43.
   PubMed Web of Science ®Google Scholar
• Zoungas S, Asmar RP. Arterial stiffness and cardiovascular outcome. Clin Exp Pharmacol Physiol. 2007;34:647–51. doi:10.1111/cep.2007.34.issue-7.
   PubMed Web of Science ®Google Scholar
• Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. 1995;26:485–90. doi:10.1161/01.HYP.26.3.485.
   PubMed Web of Science ®Google Scholar